NCT03093116 2025-07-10TRIDENT-1Turning Point Therapeutics, Inc.Phase 1/2 Recruiting500 enrolled 2 FDA
NCT04249947 2025-02-17P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)Poseida Therapeutics, Inc.Phase 1 Terminated40 enrolled
NCT03769467 2024-11-14Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)Atara BiotherapeuticsPhase 1/2 Terminated12 enrolled 8 charts
NCT02543645 2018-04-30A Study of Varlilumab and Atezolizumab in Patients With Advanced CancerCelldex TherapeuticsPhase 1 Terminated18 enrolled
NCT00841191 2014-05-14A Safety, Efficacy and Pharmacokinetic Study of Siltuximab (CNTO 328) in Participants With Solid TumorsCentocor, Inc.Phase 1/2 Completed84 enrolled